Top

Published in:

01-12-2014 | Hepatobiliary Tumors

Genetic Variants in Genes of Tricarboxylic Acid Cycle Key Enzymes Predict Postsurgical Overall Survival of Patients with Hepatocellular Carcinoma

Authors: Xiaohong Du, MSc, Shaogui Wan, PhD, Yibing Chen, MD, PhD, Ping Qu, PhD, Xiaojun Huang, PhD, Xiaohe Yu, MD, Hushan Yang, PhD, Yiguan Zhang, MD, PhD, Jinliang Xing, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2014

Abstract

Background

Metabolic reprogramming is a hallmark of cancer, including the alterations of activity and expression in tricarboxylic acid (TCA) cycle key enzymes. However, the significance of single nucleotide polymorphisms (SNPs) in genes encoding these key enzymes has not been investigated in hepatocellular carcinoma (HCC).

Methods

In this study, 17 SNPs in seven genes encoding three TCA cycle enzyme families (SDH, FH, and IDH) were genotyped in 492 HCC patients with surgical treatment and their association with overall survival (OS) was analyzed.

Results

Five SNPs in four genes were identified to be associated with OS in HCC patients. Among them, rs3935401 in the 3′ untranslated region of SDHC exhibited the most significant association (P < 0.001). The unfavorable genotype of these five SNPs showed a significant accumulative effect on the prognosis of HCC patients, with a P for trend of <0.001. Furthermore, the haplotype group consisting of wild type in rs4131826 and variant in rs3935401 was significantly associated with increased risk of death in HCC patients. Survival tree analysis indicated that variant genotype of rs3935401 was the primary risk factor contributing to the prediction of OS in HCC patients.

Conclusions

SNPs in TCA cycle key enzyme genes may serve as potential biomarkers to predict the OS in HCC patients.

Available only for authorised users

Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med. 2011;17:641–9.PubMedCentralPubMedCrossRef

Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12:685–98.PubMedCrossRef

Cardaci S, Ciriolo MR. TCA cycle defects and cancer: when metabolism tunes redox state. Int J Cell Biol. 2012;2012:161837.PubMedCentralPubMedCrossRef

Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(5454):848–51.PubMedCrossRef

Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39:178–83.PubMedCentralPubMedCrossRef

Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268–70.PubMedCrossRef

Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta. 2011;1807:1432–43.PubMedCrossRef

Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406–10.PubMedCrossRef

Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98:3387–92.PubMedCentralPubMedCrossRef

10.

Carvajal-Carmona LG, Alam NA, Pollard PJ, et al. Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations. J Clin Endocrinol Metab. 2006;91:3071–5.PubMedCrossRef

11.

Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet. 2006;43:523–6.PubMedCentralPubMedCrossRef

12.

Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12.PubMedCentralPubMedCrossRef

13.

Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–73.PubMedCentralPubMedCrossRef

14.

Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119:1901–3.PubMedCentralPubMedCrossRef

15.

Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116:2122–6.PubMedCrossRef

16.

Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125:353–5.PubMedCrossRef

17.

Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010;29:6409–17.PubMedCrossRef

18.

Shastry BS. SNPs: impact on gene function and phenotype. Methods Mol Biol. 2009;578:3–22.PubMedCrossRef

19.

Chamary JV, Parmley JL, Hurst LD. Hearing silence: non-neutral evolution at synonymous sites in mammals. Nat Rev Genet. 2006;7:98–108.PubMedCrossRef

20.

Wagner K, Damm F, Gohring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010;28:2356–64.PubMedCrossRef

21.

Ho PA, Kopecky KJ, Alonzo TA, et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children’s Oncology Group and SWOG. Blood. 2011;118:4561–6.PubMedCentralPubMedCrossRef

22.

Wang XW, Boisselier B, Rossetto M, et al. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas. Cancer. 2013;119:806–13.PubMedCrossRef

23.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef

24.

Pereira da Silva AP, El-Bacha T, Kyaw N, et al. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J. 2009;417:717–26.PubMedCrossRef

25.

Kanematsu T, Maehara Y, Matsumata T, Shirabe K, Akazawa K, Sugimachi K. Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test. Oncology. 1991;48:34–8.PubMedCrossRef

26.

Henderson AR. The bootstrap: a technique for data-driven statistics. Using computer-intensive analyses to explore experimental data. Clin Chim Acta. 2005;359:1–26.PubMedCrossRef

27.

Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12:9–22.

28.

Ooi A, Furge KA. Fumarate hydratase inactivation in renal tumors: HIF1alpha, NRF2, and “cryptic targets” of transcription factors. Chin J Cancer. 2012;31:413–20.PubMedCentralPubMedCrossRef

29.

Rakheja D, Konoplev S, Medeiros LJ, Chen W. IDH mutations in acute myeloid leukemia. Hum Pathol. 2012;43:1541–51.PubMedCrossRef

30.

Gao H, Lu Q, Liu X, et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009;100:782–5.PubMedCrossRef

31.

Huang Q, Tan Y, Yin P, et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 2013;73:4992–5002.PubMedCrossRef

32.

Chaiteerakij R, Addissie BD, Roberts LR. Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013. doi:10.1016/j.cgh.2013.10.038.

33.

Baysal BE. A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS One. 2007;2:e436.PubMedCentralPubMedCrossRef

34.

Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009;266:43–52.PubMedCentralPubMedCrossRef

35.

Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet. 2004;74:153–9.PubMedCentralPubMedCrossRef

36.

Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011–20.PubMedCentralPubMedCrossRef

Title: Genetic Variants in Genes of Tricarboxylic Acid Cycle Key Enzymes Predict Postsurgical Overall Survival of Patients with Hepatocellular Carcinoma
Authors: Xiaohong Du, MSc
Shaogui Wan, PhD
Yibing Chen, MD, PhD
Ping Qu, PhD
Xiaojun Huang, PhD
Xiaohe Yu, MD
Hushan Yang, PhD
Yiguan Zhang, MD, PhD
Jinliang Xing, MD, PhD
Publication date: 01-12-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 13/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-3876-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genetic Variants in Genes of Tricarboxylic Acid Cycle Key Enzymes Predict Postsurgical Overall Survival of Patients with Hepatocellular Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 13/2014

Factors Influencing the Length of Stay after Radical Cystectomy: Implications for Cancer Care and Perioperative Management

A Novel Method for Intraoperative Sentinel Lymph Node Detection in Prostate Cancer Patients Using Superparamagnetic Iron Oxide Nanoparticles and a Handheld Magnetometer: The Initial Clinical Experience

Commentary on the Canadian National Breast Screening Study

Centralization of Esophagectomy: How Far Should We Go?

Significance of Diaphragmatic Resections and Thoracic Chemoperfusion on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

A Risk Scoring System to Determine Recurrence in Early-Stage Type 1 Endometrial Cancer: A French Multicentre Study